

**Statement under Regulation 13(3) of SEBI (Listing Obligation
and Disclosure Requirements) Regulations, 2015, for the
Quarter ended on 30th September, 2016**

Particulars	30/09/2016
Investors' Complaints	
Pending at the beginning of the quarter	NIL
Received during the quarter	5
Disposed of during the quarter	5
Remaining unsolved at the end of the quarter	NIL

For Jenburkt Pharmaceuticals Limited



Ashish R. Shah
Company Secretary.